Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Sheet

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	(USE	as many	3116613	0 a5 i	lecessal,	"
14			$\neg \neg$	•	2	_

	Complete if Known
Application Number	10/723,955
Filing Date	November 26, 2003
First Named Inventor	CHEN, RUOPING
Group Art Unit	1646
Examiner Name	Basi, Nirmal Singh
Attorney Docket Number	AREN-007CON2 (7 US29 CON)

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	C1	Missale et al., "Dopamine receptors: from structure to function" Physiol Rev. (1998) 78:189-225 (Review)	
	C2	Sealfon et al., "Functional domains of the gonadotropin-releasing hormone receptor", Cell Mol Neurobiol. (1995) 15:25-42 (Review)	
	СЗ	Hebert et al., "Structural and functional aspects of G protein-coupled receptor oligomerization", Biochem Cell Biol. (1998) 76:1-11.	
	C4	Leung et al., "Gonadotropin-releasing hormone receptor: gene structure, expression and regulation", <i>Biol Signals</i> (1996) 5:63-9	
•	C5	Inglese et al., "Structure and mechanism of the G protein-coupled receptor kinases", J. Biol. Chem. (1993), 268:23735-8.	T
н.	C6	Ostrowski et al, Mutagenesis of the beta2-Adrenergic Receptor: How Structure Elucidates Function Annual Review of Pharmacology and Toxicology (1992), 32: 167-183	
	C7	Wong et al Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists. J Biol Chem. (1990), 265:6219-24.	
	C8	Wess et al., "Identification of a small intracellular region of the muscarinic m3 receptor as a determinant of selective coupling to PI turnover", FEBS Lett. (1989), 258:133-6	
	C9	Jackson T. Structure and function of G protein coupled receptors. Pharmacol. Ther. (1991), 50:425-42	
	C10	Yeagle et al., "Structure of the G-protein-coupled receptor, rhodopsin: a domain approach", Biochem Soc Trans. (1998), 26:520-31.	
	C11	Filizola et al., "BUNDLE: a program for building the transmembrane domains of G-protein-coupled receptors", J Comput Aided Mol Des. (1998), 12:111-8	
	C12	Gouldson et al., "Domain swapping in G-protein coupled receptor dimmers", Protein Eng. (1998), 11:1181-93.	
	C13	Eigler "Anti-inflammatory activities of cAMP-elevating agents:enhancement of IL-10 snthesis and concurrent suppression of TNF production", J. Leukocyte Biology (1998), 63: 101-107	

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute fo	r form 1449B/PT	0	Complete if Known		
			_	Application Number	10/723,955	
	INFORM	ATION DIS	CLOSURE	Filing Date	November 26, 2003	
	STATEN	IENT BY A	PPLICANT	First Named Inventor	CHEN, RUOPING	
	•			Group Art Unit	1646	
	(use as	many sheets as	necessary)	Examiner Name	Basi, Nirmal Singh	
Sheet	2	of	2	Attorney Docket Number	AREN-007CON2 (7 US29 CON)	

Moore et al., "The role of cAMP regulation in controlling inflammation", Clin. Exp. Immunol. (1995) 101: 387-389		Initials*
Dombornous et al "Differential en 14" CIENT IV 10		
Benbernou et al, "Differential regulation of IFN-y, IL-10 and inducible n itric oxide synthase in human T cells by cyuclic AMP-dependent signal transduction pathyway Immunology (1997) 91:361-368	,	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1091347_1.DOC

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.